New Delhi, April 1 GLP-1-based weight loss drugs are prescription medications used to treat type 2 diabetes and obesity, but they carry serious side effects and must only be taken under the supervision of a qualified medical specialist, the government said on Wednesday.Highlighting that...
New Delhi, April 1 – The Controller General of Drugs in India has increased regulatory scrutiny against the unauthorized sale and promotion of drugs for type 2 diabetes, also known as GLP-1 drugs, the government said on Wednesday.In recent weeks, 49 businesses across the country, including...
cardiology
diabetes
drug marketing
drug regulation
drug sales
endocrinologists
glp-1drugs
glucagon-like peptide-1 receptor agonists
india
internal medicine
medical specialties
pharmaceuticals
prescription drugs
regulatory inspections
type 2 diabetes
weight loss
The Drugs Controller of India has intensified regulatory oversight against the unauthorized sale and promotion of GLP-1-based weight loss drugs. This move comes amid growing concerns over the increasing availability of multiple generic versions of these drugs in the Indian market, through retail...
adverse effects
cardiologists
drug promotion
drug sales
drugs controller of india
endocrinologists
glp-1drugs
healthcare regulation
india
internal medicine specialists
medical supervision
pharmaceutical supply chain
prescription drugs
regulatory oversight
weight loss drugs
New Delhi, March 24 To ensure ethical pharmaceutical practices in the supply chain of weight-loss drugs of the GLP-1 class, the Drugs Controller General of India (DCGI) has intensified its regulatory surveillance against the unauthorized sale and promotion of the medications.To this end...
New Delhi, March 20 India's bioeconomy valuation surged from USD 166 billion in 2024 to USD 195 billion in 2025, reflecting strong growth across multiple biotechnology-driven industries.The BioEconomy is no longer defined solely by BioPharmaceutical or BioIndustrial. It now encompasses a...